<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02937558</url>
  </required_header>
  <id_info>
    <org_study_id>XSGO-CH01</org_study_id>
    <secondary_id>1R44DK105691-01</secondary_id>
    <nct_id>NCT02937558</nct_id>
  </id_info>
  <brief_title>CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism</brief_title>
  <official_title>A Phase 2 Proof-of-Concept Study of CSI-Glucagon™ (Continuous Subcutaneous Glucagon Infusion) to Prevent Hypoglycemia With Lower Intravenous Glucose Infusion Rates in Children up to One Year of Age With Congenital Hyperinsulinism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xeris Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Xeris Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial with
      open-label follow-up designed to assess the efficacy of Xeris Glucagon delivered as a
      continuous subcutaneous infusion to prevent hypoglycemia with lower intravenous glucose
      infusion rates in children &lt; 1 year of age with congenital hyperinsulinism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind (DB) parallel
      group study with open-label follow-up designed to evaluate the efficacy of CSI-Glucagon™ for
      the prevention of hypoglycemia with lower IV glucose infusion rates when delivered
      subcutaneously to patients up to 1 year of age with congenital hyperinsulinism. CSI-Glucagon™
      is expected to provide a better inpatient treatment option compared to the current standard
      of care.

      The study will consist of three phases:

        1. Baseline Phase: First is a baseline stabilization phase during which concomitant therapy
           with octreotide and diazoxide will be safely weaned and continuous enteric feed will be
           held constant to the degree possible, with the only factors varying being meal size and
           IV glucose infusion rate (GIR) adjusted by a set plasma glucose measurement driven
           algorithm.

        2. Blinded, Randomized Treatment Phase: Following the stabilization phase, subjects will be
           randomly assigned to blinded treatment with either glucagon or placebo, which will be
           delivered for up to 48 hours with an OmniPod® infusion pump with the controller set to a
           starting basal rate for glucagon of 5 μg/kg/hr and GIR adjustments used to maintain
           euglycemia. After 48 hours of blinded treatment, all subjects will transition to
           open-label active treatment. However, if GIR reduction from baseline is &lt; 20% at 24
           hours, subjects will be transitioned early to the open-label phase.

        3. Open-label Treatment Phase: The third study period will involve use of CSI-Glucagon™ to
           manage blood glucose with minimal GIR for up to 28 days of cumulative exposure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Clinically Meaningful Reduction in Glucose Infusion Rate (Double-Blind)</measure>
    <time_frame>Baseline to end of blinded treatment at 24 or 48 hours</time_frame>
    <description>Change from baseline in glucose infusion rate (GIR) will be determined for each subject at 24 and 48 hours from the start of blinded treatment. Subjects with a decrease in GIR ≥ 20% at 24 hours, and ≥ 33% at 48 hours will be considered to have had a clinically meaningful treatment response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in GIR (Double-Blind)</measure>
    <time_frame>Baseline to the end of blinded treatment at 24 or 48 hours</time_frame>
    <description>The groups will be compared for mean percent change in GIR from baseline to the end of the double-blind study phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Clinically Meaningful Reduction in Glucose Infusion Rate (Open-Label)</measure>
    <time_frame>Baseline to the end of open-label treatment at 72 hours</time_frame>
    <description>Change from baseline in glucose infusion rate (GIR) will be determined for each subject at the end of open-label treatment. Subjects with a decrease in GIR ≥ 33% will be considered to have had a clinically meaningful treatment response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Glucose Infusion Rate (Open-Label)</measure>
    <time_frame>Baseline to end of treatment at 72 hours</time_frame>
    <description>The groups will be compared for mean percent change in GIR from baseline to the end of the open-label study phase.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Congenital Hyperinsulinism</condition>
  <arm_group>
    <arm_group_label>CSI-Glucagon (Double-Blind Phase - 2 days)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Double-Blind Phase - 2 days)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle solution delivered as a 24-hour continuous subcutaneous infusion via a patch pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSI-Glucagon (Open-label Phase - Up to 28 days)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <description>Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide</description>
    <arm_group_label>CSI-Glucagon (Double-Blind Phase - 2 days)</arm_group_label>
    <arm_group_label>CSI-Glucagon (Open-label Phase - Up to 28 days)</arm_group_label>
    <other_name>CSI-Glucagon (continuous subcutaneous glucagon infusion)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Isotonic saline</description>
    <arm_group_label>Placebo (Double-Blind Phase - 2 days)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed with hyperinsulinism:

             a. Biochemical; detectable insulin (i.e., ≥1 µIU/L) at time of hypoglycemia (i.e,
             blood glucose &lt;50 mg/dl), and/or suppressed free fatty acids (FFA), and/or suppressed
             beta-hydroxybutyrate (BOHB) and/or glycemic response to glucagon at time of
             hypoglycemia.

          2. Absolute necessity of intravenous glucose to prevent hypoglycemia:

               1. Having failed diazoxide therapy as defined by inadequacy of 5 days maximum dose
                  of diazoxide to eliminate the need for IV glucose, not necessarily that diazoxide
                  has no effect.

               2. May be on diazoxide and/or octreotide, but these drugs will be weaned off prior
                  to randomization.

               3. May be on dextrose feeds.

          3. Patient may be a participant in other study protocols such as observational studies,
             as long as no investigational intervention has taken place within 24 hrs. prior to
             screening.

          4. Less than 12 months of age at screening.

        Exclusion Criteria:

          1. History of allergy to glucagon or excipients in the CSI-Glucagon formulation.

          2. Currently receiving, or less than 12 hours removed from IV glucagon treatment that
             resulted in a best achievable GIR &gt; 8 mg/(kg*min), prior to the start of study drug.

          3. Diazoxide naïve or within five days of starting diazoxide.

          4. Receiving steroids at doses larger than 20 mg/m2/day (hydrocortisone equivalent).

          5. Patients with sepsis.

          6. Receiving alpha or beta agonists for blood pressure support.

          7. Received an investigational or other study drug within 5 half-lives of drug.

          8. Body weight less than or equal to 2.3 kg/5.0 lbs.

          9. History of pancreatectomy and GIR &lt; 8 mg/(kg*min) after weaning of all concomitant
             therapies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA Mattel Children's Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF School of Medicine, Division of Pediatric Endocrinology</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University, St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine, Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 14, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <results_first_submitted>September 26, 2019</results_first_submitted>
  <results_first_submitted_qc>November 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 10, 2019</results_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Hyperinsulinism</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Hyperinsulinism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT02937558/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 5 subjects were randomized to active or placebo treatment during the double-blind phase of the study. All subjects completing double-blind treatment were eligible for open-label in-patient treatment with CSI Glucagon.</recruitment_details>
      <pre_assignment_details>The first enrolled subject was not deemed evaluable for responsive to glucagon based upon prior history of glucagon resistance, per investigator.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CSI-Glucagon</title>
          <description>Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
Glucagon: Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Vehicle solution delivered as a 24-hour continuous subcutaneous infusion via a patch pump.
Placebo: Isotonic saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Open-label Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CSI-Glucagon</title>
          <description>Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
Glucagon: Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Vehicle solution delivered as a 24-hour continuous subcutaneous infusion via a patch pump.
Placebo: Isotonic saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" spread="12.49"/>
                    <measurement group_id="B2" value="78.5" spread="79.90"/>
                    <measurement group_id="B3" value="46.4" spread="50.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Clinically Meaningful Reduction in Glucose Infusion Rate (Double-Blind)</title>
        <description>Change from baseline in glucose infusion rate (GIR) will be determined for each subject at 24 and 48 hours from the start of blinded treatment. Subjects with a decrease in GIR ≥ 20% at 24 hours, and ≥ 33% at 48 hours will be considered to have had a clinically meaningful treatment response.</description>
        <time_frame>Baseline to end of blinded treatment at 24 or 48 hours</time_frame>
        <population>Evaluable subjects</population>
        <group_list>
          <group group_id="O1">
            <title>CSI-Glucagon</title>
            <description>Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
Glucagon: Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Vehicle solution delivered as a 24-hour continuous subcutaneous infusion via a patch pump.
Placebo: Isotonic saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Clinically Meaningful Reduction in Glucose Infusion Rate (Double-Blind)</title>
          <description>Change from baseline in glucose infusion rate (GIR) will be determined for each subject at 24 and 48 hours from the start of blinded treatment. Subjects with a decrease in GIR ≥ 20% at 24 hours, and ≥ 33% at 48 hours will be considered to have had a clinically meaningful treatment response.</description>
          <population>Evaluable subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in GIR (Double-Blind)</title>
        <description>The groups will be compared for mean percent change in GIR from baseline to the end of the double-blind study phase.</description>
        <time_frame>Baseline to the end of blinded treatment at 24 or 48 hours</time_frame>
        <population>Evaluable subjects</population>
        <group_list>
          <group group_id="O1">
            <title>CSI-Glucagon</title>
            <description>Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
Glucagon: Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Vehicle solution delivered as a 24-hour continuous subcutaneous infusion via a patch pump.
Placebo: Isotonic saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in GIR (Double-Blind)</title>
          <description>The groups will be compared for mean percent change in GIR from baseline to the end of the double-blind study phase.</description>
          <population>Evaluable subjects</population>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.1" spread="4.5"/>
                    <measurement group_id="O2" value="1.9" spread="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Clinically Meaningful Reduction in Glucose Infusion Rate (Open-Label)</title>
        <description>Change from baseline in glucose infusion rate (GIR) will be determined for each subject at the end of open-label treatment. Subjects with a decrease in GIR ≥ 33% will be considered to have had a clinically meaningful treatment response.</description>
        <time_frame>Baseline to the end of open-label treatment at 72 hours</time_frame>
        <population>Evaluable subjects</population>
        <group_list>
          <group group_id="O1">
            <title>CSI-Glucagon</title>
            <description>Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
Glucagon: Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Vehicle solution delivered as a 24-hour continuous subcutaneous infusion via a patch pump.
Placebo: Isotonic saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Clinically Meaningful Reduction in Glucose Infusion Rate (Open-Label)</title>
          <description>Change from baseline in glucose infusion rate (GIR) will be determined for each subject at the end of open-label treatment. Subjects with a decrease in GIR ≥ 33% will be considered to have had a clinically meaningful treatment response.</description>
          <population>Evaluable subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Glucose Infusion Rate (Open-Label)</title>
        <description>The groups will be compared for mean percent change in GIR from baseline to the end of the open-label study phase.</description>
        <time_frame>Baseline to end of treatment at 72 hours</time_frame>
        <population>Evaluable subjects</population>
        <group_list>
          <group group_id="O1">
            <title>CSI-Glucagon</title>
            <description>Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
Glucagon: Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Vehicle solution delivered as a 24-hour continuous subcutaneous infusion via a patch pump.
Placebo: Isotonic saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Glucose Infusion Rate (Open-Label)</title>
          <description>The groups will be compared for mean percent change in GIR from baseline to the end of the open-label study phase.</description>
          <population>Evaluable subjects</population>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.2" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of informed consent through last administration of the investigational product, which was a maximum of 72 hours.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CSI-Glucagon (Double-Blind)</title>
          <description>Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
Glucagon: Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Vehicle solution delivered as a 24-hour continuous subcutaneous infusion via a patch pump.
Placebo: Isotonic saline</description>
        </group>
        <group group_id="E3">
          <title>CSI-Glucagon (Open-Label)</title>
          <description>Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
Glucagon: Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Khaled Junaidi</name_or_title>
      <organization>Xeris Pharmaceuticals, Inc.</organization>
      <phone>312-517-1461</phone>
      <email>xerisclintrials@xerispharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

